These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15146479)

  • 1. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
    El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
    J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
    J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.
    Darmanin C; Chevreux G; Potier N; Van Dorsselaer A; Hazemann I; Podjarny A; El-Kabbani O
    Bioorg Med Chem; 2004 Jul; 12(14):3797-806. PubMed ID: 15210146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
    Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
    Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual binding mode of the 2S4R stereoisomer of the potent aldose reductase cyclic imide inhibitor fidarestat (2S4S) in the 15 K crystal structure of the ternary complex refined at 0.78 A resolution: implications for the inhibition mechanism.
    Zhao HT; Hazemann I; Mitschler A; Carbone V; Joachimiak A; Ginell S; Podjarny A; El-Kabbani O
    J Med Chem; 2008 Mar; 51(5):1478-81. PubMed ID: 18284183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.
    Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A
    Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
    Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
    J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
    Sotriffer CA; Krämer O; Klebe G
    Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase.
    Fournier B; Bendeif el-E; Guillot B; Podjarny A; Lecomte C; Jelsch C
    J Am Chem Soc; 2009 Aug; 131(31):10929-41. PubMed ID: 19594152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
    Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
    J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
    Lee YS; Chen Z; Kador PF
    Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.
    Carbone V; Giglio M; Chung R; Huyton T; Adams J; Maccari R; Ottana R; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Mar; 45(3):1140-5. PubMed ID: 20036445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding.
    Podjarny A; Cachau RE; Schneider T; Van Zandt M; Joachimiak A
    Cell Mol Life Sci; 2004 Apr; 61(7-8):763-73. PubMed ID: 15095001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.
    Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M
    J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
    Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O
    Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
    Steuber H; Heine A; Klebe G
    J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.